More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and setting a new...
• First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026
YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1Pivotal Phase 3 CYPRESS study enrollment on track to complete by late...
Newly issued patent extends protection of proprietary solid tumor CAR-T platform to 2045
SAN JOSE, Calif., Aug. 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa"...
Neo Raises Full Year Guidance on Strong First Half-Year Performance
TORONTO, Aug. 12, 2025 /CNW/ - Neo Performance Materials Inc. ("Neo") (TSX: NEO) (OTCQX: NOPMF) reported...
The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a...
The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a...
ARLINGTON, Va., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational services, and asset optimization software, today announced its results for the three and nine months ended June 30, 2025.
LEHI, Utah, Aug. 11, 2025 /PRNewswire/ -- Boostly, the marketing platform purpose-built for restaurants, announced today that it has been awarded a U.S. patent...